Although RAAS inhibition reduces proteinuria and hypertension in cardio-renal patients, it is associated with increased risk of hyperkalemia. Prof. Rossignol shares data on the addition of patiromer in patients using spironolactone for the management of CKD with resistant hypertension.
This lecture by prof. Patrick Rossignol was part of a CME accredited symposium "RAASi and Hyperkalemia in Cardiorenal Disease: Opportunities for optimizing outcomes" held during ERA-EDTA 2019 in Budapest, Hungary.
Prof. Patrick Rossignol, MD - Professor of Therapeutics at the University of Lorraine, France.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
Funding for this educational program was provided by an unrestricted educational grant from Vifor Fresenius Medical Care Renal Pharma.The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.
- RAASi and Hyperkalaemia in Cardio Renal DiseaseManaging hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes
Prof. Matthew Weir, MD
- RAASi and Hyperkalaemia in Cardio Renal DiseaseAddressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?
Prof. van der Meer, MD, PhD